keyword
MENU ▼
Read by QxMD icon Read
search

Proton Pump Inhibitors Increase Risk

keyword
https://www.readbyqxmd.com/read/28339835/the-association-between-proton-pump-inhibitor-use-and-the-risk-of-adverse-kidney-outcomes-a-systematic-review-and-meta-analysis
#1
Surapon Nochaiwong, Chidchanok Ruengorn, Ratanaporn Awiphan, Kiatkriangkrai Koyratkoson, Chayutthaphong Chaisai, Kajohnsak Noppakun, Wilaiwan Chongruksut, Kednapa Thavorn
Background: Existing epidemiological studies illustrate that proton pump inhibitors (PPIs) may be related to adverse kidney outcomes. To date, no comprehensive meta-analysis has been conducted to evaluate and quantify this association. Methods: We performed a systematic review and meta-analysis of studies to assess the association between PPI use and the risk of adverse kidney outcomes. We searched MEDLINE, Embase, SCOPUS, Web of Science, CINAHL, Cochrane Library and grey literature with no language restrictions (through 31 October 2016)...
February 23, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28325163/proton-pump-inhibitors-as-a-risk-factor-for-norovirus-infection
#2
C Prag, M Prag, H Fredlund
Norovirus causes viral gastroenteritis, which is a major problem in health care. The disease causes death in elderly and seriously ill patients, and results in significant health costs each year. Proton pump inhibitors (PPIs) reduce gastric acidity, which is an important protection against microorganisms. We hypothesised that treatment with PPIs increases the risk of contracting norovirus infection. This has not previously been studied. The study was a retrospective case-control study, in which 192 hospitalised patients positive for norovirus in Örebro County, Sweden, were identified as cases...
March 22, 2017: Epidemiology and Infection
https://www.readbyqxmd.com/read/28321840/association-of-proton-pump-inhibitors-usage-with-risk-of-pneumonia-in-dementia-patients
#3
Sai-Wai Ho, Ying-Hock Teng, Shun-Fa Yang, Han-Wei Yeh, Yu-Hsun Wang, Ming-Chih Chou, Chao-Bin Yeh
OBJECTIVES: To determine the association between usages of proton pump inhibitors (PPIs) and subsequent risk of pneumonia in dementia patients. DESIGN: Retrospective cohort study. SETTING: Taiwanese National Health Insurance Research Database. PARTICIPANTS: The study cohort consisted of 786 dementia patients with new PPI usage and 786 matched dementia patients without PPI usage. MEASUREMENTS: The study endpoint was defined as the occurrence of pneumonia...
March 21, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/28321159/proton-pump-inhibitor-induced-collagen-expression-in-colonocytes-is-associated-with-collagenous-colitis
#4
Shiori Mori, Yui Kadochi, Yi Luo, Rina Fujiwara-Tani, Yukiko Nishiguchi, Shingo Kishi, Kiyomu Fujii, Hitoshi Ohmori, Hiroki Kuniyasu
AIM: To elucidate the role of proton pump inhibitors (PPIs) in collagenous disease, direct effect of PPI on colonocytes was examined. METHODS: Collagenous colitis is a common cause of non-bloody, watery diarrhea. Recently, there has been increasing focus on the use of proton PPIs as a risk factor for developing collagenous colitis. Mouse CT26 colonic cells were treated with PPI and/or PPI-induced alkaline media. Expression of fibrosis-associated genes was examined by RT-PCR...
March 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28319162/risk-of-acute-myocardial-infarction-in-patients-with-gastroesophageal-reflux-disease-a-nationwide-population-based-study
#5
Wei-Yi Lei, Jen-Hung Wang, Shu-Hui Wen, Chih-Hsun Yi, Jui-Sheng Hung, Tso-Tsai Liu, William C Orr, Chien-Lin Chen
OBJECTIVE: Gastroesophageal reflux disease (GERD) is a common disease which can cause troublesome symptoms and affect quality of life. In addition to esophageal complications, GERD may also be a risk factor for extra-esophageal complications. Both GERD and coronary artery disease (CAD) can cause chest pain and frequently co-exist. However, the association between GERD and acute myocardial infarction (AMI) remain unclear. The purpose of the study was to compare the incidence of acute myocardial infarction in GERD patients with an age-, gender-, and comorbidity matched population free of GERD...
2017: PloS One
https://www.readbyqxmd.com/read/28301676/deprescribing-versus-continuation-of-chronic-proton-pump-inhibitor-use-in-adults
#6
REVIEW
Taline A Boghossian, Farah Joy Rashid, Wade Thompson, Vivian Welch, Paul Moayyedi, Carlos Rojas-Fernandez, Kevin Pottie, Barbara Farrell
BACKGROUND: Proton pump inhibitors (PPIs) are a class of medications that reduce acid secretion and are used for treating many conditions such as gastroesophageal reflux disease (GERD), dyspepsia, reflux esophagitis, peptic ulcer disease, and hypersecretory conditions (e.g. Zollinger-Ellison syndrome), and as part of the eradication therapy for Helicobacter pylori bacteria. However, approximately 25% to 70% of people are prescribed a PPI inappropriately. Chronic PPI use without reassessment contributes to polypharmacy and puts people at risk of experiencing drug interactions and adverse events (e...
March 16, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28291036/potential-mechanisms-of-hematological-adverse-drug-reactions-in-patients-receiving-clozapine-in-combination-with-proton-pump-inhibitors
#7
Michał Wiciński, Mateusz M Węclewicz, Mateusz Miętkiewicz, Bartosz Malinowski, Elżbieta Grześk, Joanna Klonowska
Clozapine is a second-generation antipsychotic which has proven efficacy in treating the symptoms of schizophrenia. Although clozapine therapy is associated with a number of adverse drug reactions, it is frequently used. One of the most common adverse drug reactions is gastroesophageal reflux disease which is an indication for treatment with proton pump inhibitors (PPIs). Coadministration of clozapine and PPIs increases the risk of hematological adverse drug reactions, including neutropenia and agranulocytosis...
March 2017: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/28288458/gastric-acid-suppression-is-associated-with-an-increased-risk-of-adverse-outcomes-in-inflammatory-bowel-disease
#8
Rajesh Shah, Peter Richardson, Hong Yu, Jennifer Kramer, Jason Ken Hou
BACKGROUND: The intestinal microbiota may influence inflammatory bowel disease (IBD) activity. Histamine 2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) can alter the intestinal microbiota. The aim of this study was to assess the relationship between H2RAs, PPIs, and IBD-related outcomes. METHODS: We conducted a case-control study of IBD patients using the Veterans Health Affairs databases. Cases were defined by their first instance of an IBD-related hospitalization or surgery and the exposure of interest was H2RA or PPI use 30 days prior to the outcome...
March 14, 2017: Digestion
https://www.readbyqxmd.com/read/28284066/successful-treatment-of-proton-pump-inhibitor-induced-sporadic-fundic-gland-polyps-with-an-argon-plasma-coagulator-in-a-patient-with-polycythaemia-vera
#9
Kazuya Kato, Yoshiaki Iwasaki, Masahiko Taniguchi, Kazuhiko Onodera, Takako Kawakami, Minoru Matsuda, Mineko Higuchi, Kimitaka Kato, Yurina Kato, Susumu Tamakawa, Hiroyuki Furukawa
INTRODUCTION: Proton pump inhibitor (PPI) use is associated with the development of fundic gland polyps (FGPs); discontinuing PPIs is associated with regression of FGPs. Here, we report a rare case of non-respondent FGPs after discontinuation of PPI that were successfully treated using an argon plasma coagulator (APC). PRESENTATION OF CASE: We present the case of a 68-year-old woman with a history of polycytheamia vera. She also had gastroesophageal reflux disease (GERD) and had been taking 10 mg of omeprazole daily for the past three years...
February 24, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28283313/risk-factors-associated-with-gastroesophageal-reflux-disease-relapse-in-primary-care-patients-successfully-treated-with-a-proton-pump-inhibitor
#10
A López-Colombo, M S Pacio-Quiterio, L Y Jesús-Mejenes, J E G Rodríguez-Aguilar, M López-Guevara, A J Montiel-Jarquín, J C López-Alvarenga, E R Morales-Hernández, V R Ortiz-Juárez, L Ávila-Jiménez
BACKGROUND: There are no studies on the factors associated with gastroesophageal reflux disease (GERD) relapse in primary care patients. AIM: To identify the risk factors associated with GERD relapse in primary care patients that responded adequately to short-term treatment with a proton pump inhibitor. PATIENTS AND METHODS: A cohort study was conducted that included GERD incident cases. The patients received treatment with omeprazole for 4 weeks...
March 7, 2017: Revista de Gastroenterología de México
https://www.readbyqxmd.com/read/28280086/phentermine-induced-acute-interstitial-nephritis
#11
Emily Ximin Shao, Gregory John Wilson, Dwarakanathan Ranganathan
Acute interstitial nephritis (AIN) has a number of medication-related aetiologies. Antibiotics, proton pump inhibitors and non-steroidal anti-inflammatory drugs are common causes; however, any medication has the potential to cause drug-induced AIN. We report the first case of phentermine-induced AIN. A Caucasian woman aged 43 years presented with a 5-week history of lethargy, left-sided lower abdominal pain, nausea and vomiting. She had been taking phentermine for weight loss for 9 months and had recently ceased the medication...
March 9, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28258834/the-effect-of-omeprazole-treatment-on-the-gut-microflora-and-neutrophil-function
#12
Maja Kostrzewska, Agnieszka Świdnicka-Siergiejko, Dorota Olszańska, Grażyna Jurkowska, Marzena Garley, Wioletta Ratajczak-Wrona, Ewa Jabłońska, Jacek Jamiołkowski, Andrzej Dabrowski
BACKGROUND AND AIM: Proton pump inhibitors (PPIs) may increase the risk of Clostridium difficile infections. There are interactions between gut microbiota and innate immune cells including neutrophils. We evaluated the effect of treatment with omeprazole on the gut microflora and neutrophil function. METHODS: In 50 patients, we evaluated the effect of 4-week omeprazole treatment (n=25 with 20mg per day and n=25 with 20mg twice daily) on intragastric pH, results of stool culture and lactulose hydrogen breath test (LHBT) and neutrophil function...
March 1, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/28237709/long-term-kidney-outcomes-among-users-of-proton-pump-inhibitors-without-intervening-acute-kidney-injury
#13
Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian, Yan Yan, Ziyad Al-Aly
Proton pump inhibitor (PPI) use is associated with an increased risk of acute kidney injury (AKI), incident chronic kidney disease (CKD), and progression to end-stage renal disease (ESRD). PPI-associated CKD is presumed to be mediated by intervening AKI. However, whether PPI use is associated with an increased risk of chronic renal outcomes in the absence of intervening AKI is unknown. To evaluate this we used the Department of Veterans Affairs national databases to build a cohort of 144,032 incident users of acid suppression therapy that included 125,596 PPI and 18,436 Histamine H2 receptor antagonist (H2 blockers) consumers...
February 20, 2017: Kidney International
https://www.readbyqxmd.com/read/28230661/predicting-progression-in-barrett-s-esophagus-development-and-validation-of-the-barrett-s-esophagus-assessment-of-risk-score-bear-score
#14
Craig S Brown, Brittany Lapin, Jay L Goldstein, John G Linn, Mark S Talamonti, Joann Carbray, Michael B Ujiki
OBJECTIVE: To develop and validate a scoring tool capable of accurately predicting which patients with Barrett's esophagus (BE) will progress to dysplasia and/or esophageal adenocarcinoma. BACKGROUND: Endoscopic therapies have emerged capable of eradicating BE with high efficacy and low complication rates, but which patients should receive treatment is still debated. Current knowledge of risk factors is insufficient to allow for the accurate prediction of which patients will progress to dysplasia or adenocarcinoma...
February 22, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28223087/do-sleeve-gastrectomy-and-gastric-bypass-influence-treatment-with-proton-pump-inhibitors-4-years-after-surgery-a-nationwide-cohort
#15
Jérémie Thereaux, Thomas Lesuffleur, Sébastien Czernichow, Arnaud Basdevant, Simon Msika, David Nocca, Bertrand Millat, Anne Fagot-Campagna
BACKGROUND: Gastroesophageal reflux disease (GERD) is a common obesity-related co-morbidity that routinely is treated by continuous proton pump inhibitor (PPI) therapy. A number of concerns have been raised regarding the risk of de novo GERD or exacerbation of preexisting GERD after sleeve gastrectomy (SG). OBJECTIVE: To assess PPI use at 4 years after bariatric surgery. SETTING: French National Health Insurance. METHODS: Data were extracted from the French National Health Insurance database...
December 23, 2016: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/28219434/when-is-proton-pump-inhibitor-use-appropriate
#16
EDITORIAL
Rena Yadlapati, Peter J Kahrilas
Proton pump inhibitor (PPI) therapy is commonly used outside of Food and Drug Administration indication for a broad range of conditions such as extra-esophageal reflux and PPI-responsive esophageal eosinophilia. While this may be appropriate in some scenarios, it has also resulted in widespread inappropriate PPI use. At the same time, data suggesting adverse effects of long-term PPI therapy are multiplying, albeit mainly from low quality studies. The systematic review by Scarpignato et al. (BMC Med 14:179, 2016) addresses this dilemma with a comprehensive analysis of the risks and benefits of PPI use...
February 21, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28199356/risk-of-dementia-from-proton-pump-inhibitor-use-in-asian-population-a-nationwide-cohort-study-in-taiwan
#17
Shu-Yu Tai, Chen-Yu Chien, Deng-Chyang Wu, Kun-Der Lin, Bo-Lin Ho, Yu-Han Chang, Yang-Pei Chang
INTRODUCTION: Concerns have been raised regarding the potential association between proton pump inhibitor (PPI) use and dementia. OBJECTIVE: This study aimed to examine this association in an Asian population. METHODS: Patients initiating PPI therapy between January 1, 2000 and December 31, 2003 without a prior history of dementia were identified from Taiwan's National Health Insurance Research Database. The outcome of interest was all-cause dementia...
2017: PloS One
https://www.readbyqxmd.com/read/28185218/clinical-pharmacokinetics-and-pharmacodynamics-of-pazopanib-towards-optimized-dosing
#18
REVIEW
Remy B Verheijen, Jos H Beijnen, Jan H M Schellens, Alwin D R Huitema, Neeltje Steeghs
Pazopanib is an inhibitor of the vascular endothelial growth factor receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor and stem cell receptor c-Kit, and has been approved for the treatment of renal cell carcinoma and soft tissue sarcoma. The pharmacokinetics of pazopanib are complex and are characterized by pH-dependent solubility, large interpatient variability and low, non-linear and time-dependent bioavailability. Exposure to pazopanib is increased by both food and coadministration of ketoconazole, but drastically reduced by proton pump inhibitors...
February 10, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28177671/the-effect-of-short-term-oral-treatment-with-omeprazole-or-pantoprazole-on-the-function-of-polymorphonuclear-neutrophils
#19
Maja Kostrzewska, Marzena Garley, Wioletta Ratajczak, Ewa Jablonska, Jacek Jamiołkowski, Andrzej Dabrowski
Recent studies report an increased risk of enteric infections in patients treated with proton pump inhibitors (PPIs). Polymorphonuclear neutrophils (PMNs) play a key role in host response to bacterial infection. We have evaluated the effect of omeprazole and pantoprazole treatment on the PMNs function. Fifteen patients were treated with omeprazole 20 mg daily and 15 patients with pantoprazole 40 mg daily for 7 days. Treatment with omeprazole or pantoprazole had no effect on spontaneous nitroblue tetrazolium (NBT) test results...
January 22, 2017: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28175211/p720-use-of-proton-pump-inhibitors-associated-with-a-markedly-increased-risk-of-microscopic-colitis
#20
O Bonderup, G Lauge Nielsen, M Dall, A Pottegård, J Hallas
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
keyword
keyword
119228
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"